On September 14, the FDA set aside four hours to hear how psychedelic therapies might work in regulated settings. More than 80 speakers took part.
Reports said more than 18,000 people registered for the public hearing, while over 200 requested to speak. Regulators and physicians showed growing interest in the treatments’ potential to help people with mental illness. Patients and veterans’ organizations also took part. But discussion of rescheduling or reclassification alone cannot establish how these therapies would be delivered safely and at scale.
The need is substantial. More than 62 million American adults live with mental illness, and tens of millions have few treatments that work. Nearly one in three patients treated for major depressive disorder gets no meaningful relief from medication.
An executive order signed in April 2026 directed HHS to accelerate research and regulatory evaluation of psychedelic treatments for serious mental disorders. The order did not itself change the drugs’ Schedule I status.
Regulatory attention cannot build delivery systems
The gap matters in a field where existing care falls short for many patients. For PTSD, first-line treatments have an average nonresponse rate of 40%. In July 2026, the FDA issued guidance for psychedelic clinical trials. It addresses blinding and safety monitoring, along with how researchers assess efficacy, as described in coverage of the FDA guidance.
In June 2024, an FDA advisory committee voted 9–2 that evidence did not establish MDMA-assisted therapy’s effectiveness for PTSD and 10–1 that its benefits did not outweigh its risks. The FDA rejected Lykos Therapeutics’ application in August 2024, concluding the submitted evidence did not establish safety and effectiveness at the required level.
Access depends on the systems around treatment
Access barriers extend beyond psychedelic medicine. A report on CAR-T access describes geographic and eligibility obstacles for people seeking clinical trials. Potential medical benefit does not ensure patients can reach or receive care.
As of early October 2026, no psychedelic drug had received FDA approval. Psilocybin remained a Schedule I substance. MDMA and LSD did too, with U.S. access largely limited to authorized research, according to a regulatory status report.
